Gavrilova Tatyana, Schulz Eduard, Mina Alain
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Immune Deficiency-Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cancers (Basel). 2024 Aug 6;16(16):2780. doi: 10.3390/cancers16162780.
Immunotherapy has revolutionized the treatment of myeloid oncologic diseases, particularly for patients resistant to chemotherapy or ineligible for allogeneic stem cell transplantation due to age or fitness constraints. As our understanding of the immunopathogenesis of myeloid malignancies expands, so too do the treatment options available to patients. Immunotherapy in myeloid malignancies, however, faces numerous challenges due to the dynamic nature of the disease, immune dysregulation, and the development of immune evasion mechanisms. This review outlines the progress made in the field of immunotherapy for myeloid malignancies, addresses its challenges, and provides insights into future directions in the field.
免疫疗法彻底改变了髓系肿瘤疾病的治疗方式,尤其适用于对化疗耐药或因年龄或身体状况限制而不适合进行异基因干细胞移植的患者。随着我们对髓系恶性肿瘤免疫发病机制的理解不断深入,患者可获得的治疗选择也日益增多。然而,由于疾病的动态性质、免疫失调以及免疫逃逸机制的发展,髓系恶性肿瘤的免疫疗法面临着诸多挑战。本综述概述了髓系恶性肿瘤免疫治疗领域取得的进展,探讨了其面临的挑战,并对该领域的未来发展方向提供了见解。